Kaveh Zakeri, MD
Radiation Oncology · Charlotte Hall, MDNPI 1326380486
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,840 of the $8,702 with a category attached, or 78.6%. EMD Serono, Inc. accounts for 83.6% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $7,159 and has fallen 85.6% since, to $1,028 in 2025.
Across 61 payments — averaging $142.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$7K
- AstraZeneca$283
- Novartis$221
- Merck$158
- Eisai Inc.$138
- Genentech USA, Inc.$99
- plus $525 from 12 others
What the payments were for
- Consulting fees$6,84079%
- Travel & lodging$2203%
- Food & beverage$1,64219%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 5 | $7,278 |
| AstraZeneca | 10 | $283 |
| Novartis | 11 | $221 |
| Merck | 5 | $158 |
| Eisai Inc. | 6 | $138 |
| Genentech USA, Inc. | 3 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $76 |
| Pfizer | 3 | $65 |
| Johnson & Johnson | 3 | $64 |
| Astellas Pharma US Inc | 2 | $52 |
| Springworks Therapeutics, Inc. | 2 | $50 |
| Incyte Corporation | 2 | $48 |
| Sobi, Inc | 2 | $46 |
| AbbVie | 1 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $28 |
| Puma Biotechnology, Inc. | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Verity Pharmaceuticals Inc. | 1 | $18 |
How this compares
$8,702 in reported general payments places this provider in the 85th percentile of 108 radiation oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine Hcl ViscousLidocaine Hcl | 21 | $594 |
| Oxycodone Hcl | 16 | $221 |
| Silver Sulfadiazine | 11 | $145 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Charlotte Hall
- Sahaja AcharyaBaltimore$200K
- Arpit ChhabraBaltimore$97K
- Robert BrooklandTowson$34K
- Lawrence KleinbergBaltimore$34K
- Danny SongBaltimore$32K
- Jason MolitorisBaltimore$26K
- Kristin RedmondBaltimore$17K
- John MansuetiBerlin$11K
- Avani RaoBaltimore$10K
- Lawrence ShombertCumberland$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.